BWA-522
Based on 1 Customer Validation
BWA-522 is an orally active PROTAC degrader targeting full-length androgen receptor (AR-FL) and androgen receptor splice variant 7 (AR-V7). BWA-522 antagonizes the N-terminal domain (AR-NTD) of the androgen receptor, suppresses AR downstream signaling proteins and induces cancer cells apoptosis. BWA-522 inhibits tumor growth in LNCaP xenograft mouse model. BWA-522 can be used for the research of prostate cancer.
(Pink: Androgen Receptor ligand (HY-109070); Blue: Cereblon ligand (HY-14658); Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.04%
- CAS No.: 3042820-12-9
- Formule: C43H51ClN4O7
- Masse moléculaire:771.34
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
|
Cereblon |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CWR22R | IC50 |
4.08 μM
Compound: 28; BWA-522
|
Antiproliferative activity against enzalutamide-resistant human 22Rv1 cells assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
Antiproliferative activity against enzalutamide-resistant human 22Rv1 cells assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
|
[PMID: 37556600] |
| LNCaP | IC50 |
1.07 μM
Compound: 28; BWA-522
|
Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
|
[PMID: 37556600] |
| VCaP | IC50 |
5.59 μM
Compound: 28; BWA-522
|
Antiproliferative activity against human VCaP cells assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
Antiproliferative activity against human VCaP cells assessed as reduction in cell viability incubated for 6 days by CCK-8 assay
|
[PMID: 37556600] |
BWA-522 (0.03-30 μM; 3-48 h) dose- and time-dependently degrades both AR-FL and AR-V7 in LNCaP, VCaP, and 22Rv1 prostate cancer cells via the ubiquitin proteasome system and CRBN/cullin 4A ubiquitin ligase, with DC50 values ranging from 0.67 to 3.45 μM[1].
BWA-522 (6 days) potently inhibits the growth of AR-dependent LNCaP, VCaP, and Enzalutamide (HY-70002)-resistant 22Rv1 prostate cancer cells with IC50 values ranging from 1.07 to 5.59 μM, while sparing AR-independent and normal prostate cells[1].
BWA-522 (1-10 μM; 2 weeks) dose-dependently inhibits long-term colony formation of LNCaP and 22Rv1 prostate cancer cells[1].
BWA-522 (1-10 μM; 48 h) dose-dependently suppresses AR downstream signaling proteins and induces apoptosis in LNCaP and VCaP prostate cancer cells[1].
BWA-522 has a low risk of cardiotoxicity, as it exhibits minimal inhibition of the hERG channel with an IC50 greater than 10 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:LNCaP, VCaP, and 22Rv1 prostate cancer cells
-
Concentration:10 μM
-
Incubation Time:3, 6, 9, 12, 24, 48 h
-
Result:Time-dependently degraded both AR-FL and AR-V7.
-
Cell Line:LNCaP, VCaP human prostate cancer cells
-
Concentration:1, 5, 10 μM
-
Incubation Time:48 h
-
Result:Reduced TMPRSS2, FKBP51, and PSA levels.
Induced significant cleavage of PARP-1 and caspase-3 .
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | CL | F |
|---|---|---|---|---|---|---|---|---|
| Mice[1] | 2 mg/kg | i.v. | 8.2 ± 1.0 h | 0.1 ± 0.0 h | 782 ± 275 ng/mL | 3018 ± 326 ng·h/mL | 594 ± 49 mL/h/kg | / |
| Mice[1] | 10 mg/kg | p.o. | 7.9 ± 0.7 h | 4.7 ± 1.2 h | 376 ± 55 ng/mL | 5947 ± 729 ng·h/mL | / | 40.5 ± 4.6 % |
| Dog[1] | 1 mg/kg | i.v. | 9.9 ± 1.1 h | 0.1 ± 0.0 h | 150.0 ± 24.8 ng/mL | 919.0 ± 181.0 ng·h/mL | 932.0 ± 227.0 mL/h/kg | / |
| Dog[1] | 5 mg/kg | p.o. | 31.2 ± 15.9 h | 2.8 ± 2.2 h | 97.3 ± 56.4 ng/mL | 1411.0 ± 678.0 ng·h/mL | / | 69.3 ± 0.5 % |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LNCaP xenograft-bearing NOD SCID mice (6 weeks old)[1]
-
Dosage:20 mg/kg; 60 mg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Achieved 26% tumor growth inhibition relative to vehicle control at 20 mg/kg.
Achieved 76% tumor growth inhibition relative to vehicle control at 60 mg/kg.
Caused no noticeable body weight loss throughout the study.
Chemical Information
-
CAS No. 3042820-12-9
-
Appearance Solid
-
Masse moléculaire 771.34
-
Formule C43H51ClN4O7
-
Color Light yellow to yellow
-
SMILES
CC(C1=CC=C(OC[C@H](O)CCl)C=C1)(C)C(C=C2)=CC=C2OCC3CCN(CC4CCN(C5=CC=C6C(C(N(C7CCC(NC7=O)=O)C6=O)=O)=C5)CC4)CC3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 90 mg/mL (116.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2964 mL | 6.4822 mL | 12.9645 mL | 32.4111 mL |
| 5 mM | 0.2593 mL | 1.2964 mL | 2.5929 mL | 6.4822 mL | |
| 10 mM | 0.1296 mL | 0.6482 mL | 1.2964 mL | 3.2411 mL | |
| 15 mM | 0.0864 mL | 0.4321 mL | 0.8643 mL | 2.1607 mL | |
| 20 mM | 0.0648 mL | 0.3241 mL | 0.6482 mL | 1.6206 mL | |
| 25 mM | 0.0519 mL | 0.2593 mL | 0.5186 mL | 1.2964 mL | |
| 30 mM | 0.0432 mL | 0.2161 mL | 0.4321 mL | 1.0804 mL | |
| 40 mM | 0.0324 mL | 0.1621 mL | 0.3241 mL | 0.8103 mL | |
| 50 mM | 0.0259 mL | 0.1296 mL | 0.2593 mL | 0.6482 mL | |
| 60 mM | 0.0216 mL | 0.1080 mL | 0.2161 mL | 0.5402 mL | |
| 80 mM | 0.0162 mL | 0.0810 mL | 0.1621 mL | 0.4051 mL | |
| 100 mM | 0.0130 mL | 0.0648 mL | 0.1296 mL | 0.3241 mL |
BWA-522 Related Classifications
HY-149433 Related Classifications
Powered by Bioz